🚀 VC round data is live in beta, check it out!
Guard Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Guard Therapeutics and similar public comparables like Strategic Partners, Geovax Labs, Newbury Pharmaceuticals, Modus Therapeutics and more.
Guard Therapeutics Overview
About Guard Therapeutics
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
Founded
1974
HQ
Employees
14
Website
Sectors
Financials (FY)
Market Cap
$4M
Guard Therapeutics Financials
Guard Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($11M).
In the same fiscal year, Guard Therapeutics generated — in gross profit, ($11M) in EBITDA losses, and had net loss of ($11M).
Guard Therapeutics P&L
In the most recent fiscal year, Guard Therapeutics reported revenue of — and EBITDA of ($11M).
Guard Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($11M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($11M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Guard Therapeutics Stock Performance
Guard Therapeutics has current market cap of $4M.
Market Cap Evolution
Guard Therapeutics' stock price is $0.18.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $4M | 1.4% | XXX | XXX | XXX | $-0.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGuard Therapeutics Valuation Multiples
Guard Therapeutics trades at 0.4x EV/EBITDA.
Guard Therapeutics Financial Valuation Multiples
As of March 11, 2026, Guard Therapeutics has market cap of $4M.
Equity research analysts estimate Guard Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guard Therapeutics has a P/E ratio of (0.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV (current) | ($4M) | XXX | ($4M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 0.4x | XXX | XXX | XXX |
| P/E | — | XXX | (0.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Guard Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Guard Therapeutics Margins & Growth Rates
Guard Therapeutics' revenue in the last fiscal year grew by —.
Guard Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (15%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Guard Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Strategic Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Geovax Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Newbury Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Modus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guard Therapeutics M&A Activity
Guard Therapeutics acquired XXX companies to date.
Last acquisition by Guard Therapeutics was on XXXXXXXX, XXXXX. Guard Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Guard Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGuard Therapeutics Investment Activity
Guard Therapeutics invested in XXX companies to date.
Guard Therapeutics made its latest investment on XXXXXXXX, XXXXX. Guard Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Guard Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Guard Therapeutics
| When was Guard Therapeutics founded? | Guard Therapeutics was founded in 1974. |
| Where is Guard Therapeutics headquartered? | Guard Therapeutics is headquartered in Sweden. |
| How many employees does Guard Therapeutics have? | As of today, Guard Therapeutics has over 14 employees. |
| Is Guard Therapeutics publicly listed? | Yes, Guard Therapeutics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Guard Therapeutics? | Guard Therapeutics trades under GUARD ticker. |
| When did Guard Therapeutics go public? | Guard Therapeutics went public in 2013. |
| Who are competitors of Guard Therapeutics? | Guard Therapeutics main competitors are Strategic Partners, Geovax Labs, Newbury Pharmaceuticals, Modus Therapeutics. |
| What is the current market cap of Guard Therapeutics? | Guard Therapeutics' current market cap is $4M. |
| Is Guard Therapeutics profitable? | No, Guard Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.